PENAO Pty Ltd

PENAO is an Australian start-up biotechnology company developing a portfolio within its clinical-stage product to treat cancer

The key date of the first-in-human phase I clinical trial of Beroni Group’s new anti-cancer drug PENAO in advanced solid tumors was disclosed for the first time

The Company

PENAO Pty Ltd was incorporated in Sydney, Australia on the 24th June 2019. It is registered with the Australian Securities and Investments Commission (ASIC) and the Australian Company Number (ACN) is 634 333 387.

In addition to an initial $2,350,000 investment from Beroni, the Company benefits from the Australian government’s R&D rebate which gives an annual cash return of 43.5% from all domestic and overseas qualifying R&D spend. (After 1 July 2021, the R&D rebate was changed to the company tax rate plus an 18.5% premium).

In FY 2022-3, PENAO Pty Ltd received a rebate of $419,018.18  PENAO Pty Ltd has now received a total of $668,872.36 R&D rebate, including $249,854.18 from the truncated Jan-Jun 2021 FY.